Dasatinib (Sprycel)

Multi-kinase inhibitor originally developed for Philadelphia chromosome-positive CML and ALL. Inhibits Src family kinases, BCR-ABL, c-Kit, PDGFR, and ephrin receptor kinases. Senolytic activity derives from disruption of the senescent cell anti-apoptotic pathway (SCAP) network, specifically targeting pro-survival signaling through Src, PI3K, and tyrosine kinase-dependent pathways that keep senescent cells alive.

Half-life

3-5 hours

Bioavailability

~15-25% (oral, pH-dependent)

Route

oral

Evidence tier

T1 — Multiple RCTs

Optimization pillars

anti-aging · cellular-health

References

4 peer-reviewed

Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative

50 mg single dose

Combined with quercetin in D+Q senolytic protocol

moderate

100 mg for 2-3 consecutive days

D+Q monthly senolytic cycling

aggressive

100–140 mg/day

Oncologic dose (CML, continuous)

Monitoring

wbc
rbc
hemoglobin
hematocrit
alt
ast
creatinine
lipid-panel
hs-crp
fasting-glucose

Contraindications

thrombocytopenia
neutropenia
pulmonary-arterial-hypertension
long-qt-syndrome
concurrent-strong-cyp3a4-inhibitors
pregnancy

References

PMID:25754370The Achilles heel of senescent cells: from transcriptome to senolytic drugs — Aging Cell, 2015
PMID:30279143Senolytic drugs: from discovery to translation — J Intern Med, 2018
PMID:30907060Senolytics decrease senescent cells in humans: preliminary report from a clinical trial — EBioMedicine, 2019
PMID:31542391Senolytic therapy alleviates physiological human brain aging — Nat Med, 2019

Notes

Dasatinib is a prescription cancer drug repurposed as a longevity intervention. The Kirkland and Tchkonia group at Mayo published the foundational paper in 2015 identifying the senescent cell anti-apoptotic pathways and showing that dasatinib plus quercetin (D+Q) could selectively eliminate them. The first human pilot data landed in 2019 — diabetic kidney disease patients showing reduced senescent cell burden after intermittent D+Q dosing. Evidence tier 1 for CML, tier 2 for the senolytic application. The intermittent dosing schedule is critical. This is a hit-and-run strategy, not chronic therapy. Two to three days per month at most.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See Dasatinib (Sprycel) in a protocol matched to you